MRD in Philadelphia Chromosome-Positive ALL: Methodologies and Clinical Implications.
Acute Lymphoblastic Leukemia
Blinatumomab
Inotuzumab Ozogamicin
Measurable Residual Disease
Philadelphia Positive
Tisagenlecleucel
Journal
Current hematologic malignancy reports
ISSN: 1558-822X
Titre abrégé: Curr Hematol Malig Rep
Pays: United States
ID NLM: 101262565
Informations de publication
Date de publication:
18 Jun 2024
18 Jun 2024
Historique:
accepted:
08
06
2024
medline:
18
6
2024
pubmed:
18
6
2024
entrez:
18
6
2024
Statut:
aheadofprint
Résumé
Measurable residual disease (MRD) is integral in the management of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). This review discusses the current methods used to evaluate MRD as well as the interpretation, significance, and incorporation of MRD in current practice. New molecular technologies have allowed the detection of MRD to levels as low as 10
Identifiants
pubmed: 38888822
doi: 10.1007/s11899-024-00736-9
pii: 10.1007/s11899-024-00736-9
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Samra B, Jabbour E, Ravandi F, Kantarjian H, Short NJ. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. J Hematol OncolJ Hematol Oncol. 2020;13:70. https://doi.org/10.1186/s13045-020-00905-2 .
doi: 10.1186/s13045-020-00905-2
Saleh K, Fernandez A, Pasquier F. Treatment of Philadelphia chromosome-positive Acute lymphoblastic leukemia in adults. Cancers. 2022;14:1805. https://doi.org/10.3390/cancers14071805 .
doi: 10.3390/cancers14071805
pubmed: 35406576
pmcid: 8997772
Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009;113:4153–62. https://doi.org/10.1182/blood-2008-11-185132 .
doi: 10.1182/blood-2008-11-185132
pubmed: 19141862
Short NJ, Jabbour E, Albitar M, De Lima M, Gore L, Jorgensen J, et al. Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: a consensus of north American experts. Am J Hematol. 2019;94:257–65. https://doi.org/10.1002/ajh.25338 .
doi: 10.1002/ajh.25338
pubmed: 30394566
Pulsipher MA, Han X, Maude SL, Laetsch TW, Qayed M, Rives S, et al. Next-generation sequencing of minimal residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young adults with Acute Lymphoblastic Leukemia. Blood Cancer Discov. 2022;3:66–81. https://doi.org/10.1158/2643-3230.BCD-21-0095 .
doi: 10.1158/2643-3230.BCD-21-0095
pubmed: 35019853
Lee S, Kim D-W, Cho B-S, Yoon J-H, Shin S-H, Yahng S-A, et al. Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia. 2012;26:2367–74. https://doi.org/10.1038/leu.2012.164 .
doi: 10.1038/leu.2012.164
pubmed: 22705993
Zhou Y, Slack R, Jorgensen JL, Wang SA, Rondon G, de Lima M, et al. The impact of peri-transplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2014;14:319–26. https://doi.org/10.1016/j.clml.2014.01.002 .
doi: 10.1016/j.clml.2014.01.002
pubmed: 24548609
pmcid: 5614489
Sun J, Kroeger JL, Markowitz J. Introduction to Multiparametric Flow Cytometry and Analysis of High-Dimensional Data. In: Markowitz J, editor. Transl. Bioinforma. Ther. Dev. Volume 2194. New York, NY: Springer US; 2021. pp. 239–53. https://doi.org/10.1007/978-1-0716-0849-4_13 .
doi: 10.1007/978-1-0716-0849-4_13
Riva G, Nasillo V, Ottomano AM, Bergonzini G, Paolini A, Forghieri F, et al. Multiparametric Flow Cytometry for MRD Monitoring in Hematologic malignancies: clinical applications and New challenges. Cancers. 2021;13:4582. https://doi.org/10.3390/cancers13184582 .
doi: 10.3390/cancers13184582
pubmed: 34572809
pmcid: 8470441
Wood BL. Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry. Cytometry B Clin Cytom. 2016;90:47–53. https://doi.org/10.1002/cyto.b.21239 .
doi: 10.1002/cyto.b.21239
pubmed: 25906832
Theunissen P, Mejstrikova E, Sedek L, Van Der Sluijs-Gelling AJ, Gaipa G, Bartels M, et al. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood. 2017;129:347–57. https://doi.org/10.1182/blood-2016-07-726307 .
doi: 10.1182/blood-2016-07-726307
pubmed: 27903527
pmcid: 5291958
Dekker SE, Rea D, Cayuela J-M, Arnhardt I, Leonard J, Heuser M. Using measurable residual disease to Optimize Management of AML, ALL, and chronic myeloid leukemia. Am Soc Clin Oncol Educ Book. 2023;e390010. https://doi.org/10.1200/EDBK_390010 .
Allen P, Phillips C, Wilkes S, Wright G, Newland A. Principles of the polymerase chain reaction in Haematology. Hematology. 1997;2:249–56. https://doi.org/10.1080/10245332.1997.11746344 .
doi: 10.1080/10245332.1997.11746344
pubmed: 27406870
Kruse A-A, Kim, Ruan P. Minimal residual disease detection in Acute Lymphoblastic Leukemia. Int J Mol Sci. 2020;21:1054. https://doi.org/10.3390/ijms21031054 .
doi: 10.3390/ijms21031054
pubmed: 32033444
pmcid: 7037356
Abou Dalle I, Jabbour E, Short NJ. Evaluation and management of measurable residual disease in acute lymphoblastic leukemia. Ther Adv Hematol. 2020;11:204062072091002. https://doi.org/10.1177/2040620720910023 .
doi: 10.1177/2040620720910023
Hein K, Short N, Jabbour E, Yilmaz M. Clinical value of measurable residual disease in Acute Lymphoblastic Leukemia. Blood Lymphat Cancer Targets Ther. 2022;12:7–16. https://doi.org/10.2147/BLCTT.S270134 .
doi: 10.2147/BLCTT.S270134
Gaipa G, Cazzaniga G, Valsecchi MG, Panzer-Grumayer R, Buldini B, Silvestri D, et al. Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia. Haematologica. 2012;97:1582–93. https://doi.org/10.3324/haematol.2011.060426 .
doi: 10.3324/haematol.2011.060426
pubmed: 22581001
pmcid: 3487561
Cazzaniga G, De Lorenzo P, Alten J, Röttgers S, Hancock J, Saha V, et al. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies. Haematologica. 2018;103:107–15. https://doi.org/10.3324/haematol.2017.176917 .
doi: 10.3324/haematol.2017.176917
pubmed: 29079599
pmcid: 5777198
Hovorkova L, Zaliova M, Venn NC, Bleckmann K, Trkova M, Potuckova E, et al. Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology. Blood. 2017;129:2771–81. https://doi.org/10.1182/blood-2016-11-749978 .
doi: 10.1182/blood-2016-11-749978
pubmed: 28331056
Saygin C, Cannova J, Stock W, Muffly L. Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients. Haematologica. 2022;107:2783–93. https://doi.org/10.3324/haematol.2022.280638 .
doi: 10.3324/haematol.2022.280638
pubmed: 36453516
pmcid: 9713546
Van Der Velden VHJ, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21:604–11. https://doi.org/10.1038/sj.leu.2404586 .
doi: 10.1038/sj.leu.2404586
pubmed: 17287850
Pfeifer H, Cazzaniga G, Van Der Velden VHJ, Cayuela JM, Schäfer B, Spinelli O, et al. Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1. Leukemia. 2019;33:1910–22. https://doi.org/10.1038/s41375-019-0413-0 .
doi: 10.1038/s41375-019-0413-0
pubmed: 30858550
Della Starza I, De Novi LA, Santoro A, Salemi D, Tam W, Cavalli M, et al. Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia. Leuk Lymphoma. 2019;60:2838–40. https://doi.org/10.1080/10428194.2019.1607325 .
doi: 10.1080/10428194.2019.1607325
pubmed: 31050551
Vogelstein B, Kinzler KW, Digital PCR. Proc Natl Acad Sci. 1999;96:9236–41. https://doi.org/10.1073/pnas.96.16.9236 .
doi: 10.1073/pnas.96.16.9236
pubmed: 10430926
pmcid: 17763
Taylor SC, Laperriere G, Germain H. Droplet Digital PCR versus qPCR for gene expression analysis with low abundant targets: from variable nonsense to publication quality data. Sci Rep. 2017;7:2409. https://doi.org/10.1038/s41598-017-02217-x .
doi: 10.1038/s41598-017-02217-x
pubmed: 28546538
pmcid: 5445070
Ansuinelli M, Della Starza I, Lauretti A, Elia L, Siravo V, Messina M, et al. Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia-positive acute lymphoblastic leukaemia. Hematol Oncol. 2021;39:680–6. https://doi.org/10.1002/hon.2913 .
doi: 10.1002/hon.2913
pubmed: 34402088
pmcid: 9292453
Coccaro N, Anelli L, Zagaria A, Casieri P, Tota G, Orsini P, et al. Droplet Digital PCR is a Robust Tool for monitoring minimal residual disease in adult Philadelphia-positive Acute Lymphoblastic Leukemia. J Mol Diagn. 2018;20:474–82. https://doi.org/10.1016/j.jmoldx.2018.03.002 .
doi: 10.1016/j.jmoldx.2018.03.002
pubmed: 29625246
Coccaro N, Anelli L, Zagaria A, Specchia G, Albano F. Next-generation sequencing in Acute Lymphoblastic Leukemia. Int J Mol Sci. 2019;20:2929. https://doi.org/10.3390/ijms20122929 .
doi: 10.3390/ijms20122929
pubmed: 31208040
pmcid: 6627957
Theunissen PMJ, De Bie M, Van Zessen D, De Haas V, Stubbs AP, Van Der Velden VHJ. Next-generation antigen receptor sequencing of paired diagnosis and relapse samples of B-cell acute lymphoblastic leukemia: clonal evolution and implications for minimal residual disease target selection. Leuk Res. 2019;76:98–104. https://doi.org/10.1016/j.leukres.2018.10.009 .
doi: 10.1016/j.leukres.2018.10.009
pubmed: 30389174
Theunissen PMJ, Van Zessen D, Stubbs AP, Faham M, Zwaan CM, Van Dongen JJM, et al. Antigen receptor sequencing of paired bone marrow samples shows homogeneous distribution of acute lymphoblastic leukemia subclones. Haematologica. 2017;102:1869–77. https://doi.org/10.3324/haematol.2017.171454 .
doi: 10.3324/haematol.2017.171454
pubmed: 28860343
pmcid: 5664391
Thol F, Kölking B, Damm F, Reinhardt K, Klusmann J, Reinhardt D, et al. Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3 ‐ITD or NPM1 mutations. Genes Chromosomes Cancer. 2012;51:689–95. https://doi.org/10.1002/gcc.21955 .
doi: 10.1002/gcc.21955
pubmed: 22454318
Muffly L, Sundaram V, Chen C, Yurkiewicz I, Kuo E, Burnash S, et al. Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia. Blood Adv. 2021;5:3147–51. https://doi.org/10.1182/bloodadvances.2021004234 .
doi: 10.1182/bloodadvances.2021004234
pubmed: 34424318
pmcid: 8405199
Monter A, Nomdedéu JF. ClonoSEQ assay for the detection of lymphoid malignancies. Expert Rev Mol Diagn. 2019;19:571–8. https://doi.org/10.1080/14737159.2019.1627877 .
doi: 10.1080/14737159.2019.1627877
pubmed: 31179776
Short NJ, Jabbour E, Macaron W, Ravandi F, Jain N, Kanagal-Shamanna R, et al. Ultrasensitive NGS MRD assessment in Ph + ALL: prognostic impact and correlation with RT‐PCR for BCR::ABL1. Am J Hematol. 2023;98:1196–203. https://doi.org/10.1002/ajh.26949 . This study evaluated the clinical impact of next-generation sequencing (NGS)-based assessment of MRD and its correlation to the more commonly used RT-PCR method.
Coustan-Smith E, Sancho J, Hancock ML, Razzouk BI, Ribeiro RC, Rivera GK, et al. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood. 2002;100:2399–402. https://doi.org/10.1182/blood-2002-04-1130 .
doi: 10.1182/blood-2002-04-1130
pubmed: 12239148
van der Velden VHJ, Jacobs DCH, Wijkhuijs AJM, Comans-Bitter WM, Willemse MJ, Hählen K, et al. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia. 2002;16:1432–6. https://doi.org/10.1038/sj.leu.2402636 .
doi: 10.1038/sj.leu.2402636
pubmed: 12145681
van Rhee F, Marks DI, Lin F, Szydlo RM, Hochhaus A, Treleaven J, et al. Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow. Leukemia. 1995;9:329–35.
pubmed: 7869772
Logan AC, Vashi N, Faham M, Carlton V, Kong K, Buño I, et al. Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl. 2014;20:1307–13. https://doi.org/10.1016/j.bbmt.2014.04.018 .
doi: 10.1016/j.bbmt.2014.04.018
Tierens A, Stockley TL, Campbell C, Fulcher J, Leber B, McCready E, et al. Consensus recommendations for MRD Testing in Adult B-Cell Acute Lymphoblastic Leukemia in Ontario. Curr Oncol. 2021;28:1376–87. https://doi.org/10.3390/curroncol28020131 .
doi: 10.3390/curroncol28020131
pubmed: 33808300
pmcid: 8025812
Ravandi F, Jorgensen JL, Thomas DA, O’Brien S, Garris R, Faderl S, et al. Detection of MRD may predict the outcome of patients with Philadelphia chromosome–positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013;122:1214–21. https://doi.org/10.1182/blood-2012-11-466482 .
doi: 10.1182/blood-2012-11-466482
pubmed: 23836561
pmcid: 3976223
Zuna J, Hovorkova L, Krotka J, Koehrmann A, Bardini M, Winkowska L, et al. Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease. Leukemia. 2022;36:2793–801. https://doi.org/10.1038/s41375-022-01668-0 .
doi: 10.1038/s41375-022-01668-0
pubmed: 35933523
Kim R, Rousselot P, Cayuela J-M, Chalandon Y, Passet M, Thomas X, et al. Frequency and outcome of Philadelphia chromosome-positive Acute Lymphoblastic leukemia with BCR-ABL1 clonal hematopoiesis after Blast Clearance: results from the Graaph-2014 Trial. Blood. 2021;138:3478–3478. https://doi.org/10.1182/blood-2021-150126 .
doi: 10.1182/blood-2021-150126
Beldjord K, Chevret S, Asnafi V, Huguet F, Boulland M-L, Leguay T, et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood. 2014;123:3739–49. https://doi.org/10.1182/blood-2014-01-547695 .
doi: 10.1182/blood-2014-01-547695
pubmed: 24740809
Ribera J-M, Oriol A, Morgades M, Montesinos P, Sarrà J, González-Campos J, et al. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. J Clin Oncol off J Am Soc Clin Oncol. 2014;32:1595–604. https://doi.org/10.1200/JCO.2013.52.2425 .
doi: 10.1200/JCO.2013.52.2425
Short NJ, Jabbour E, Sasaki K, Patel K, O’Brien SM, Cortes JE, et al. Impact of complete molecular response on survival in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia. Blood. 2016;128:504–7. https://doi.org/10.1182/blood-2016-03-707562 .
doi: 10.1182/blood-2016-03-707562
pubmed: 27235138
pmcid: 4965905
Daver N, Thomas D, Ravandi F, Cortes J, Garris R, Jabbour E, et al. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica. 2015;100:653–61. https://doi.org/10.3324/haematol.2014.118588 .
doi: 10.3324/haematol.2014.118588
pubmed: 25682595
pmcid: 4420214
Yanada M, Sugiura I, Takeuchi J, Akiyama H, Maruta A, Ueda Y, et al. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy. Br J Haematol. 2008;143:503–10. https://doi.org/10.1111/j.1365-2141.2008.07377.x .
doi: 10.1111/j.1365-2141.2008.07377.x
pubmed: 18986386
Foà R, Vitale A, Vignetti M, Meloni G, Guarini A, De Propris MS, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia. Blood. 2011;118:6521–8. https://doi.org/10.1182/blood-2011-05-351403 .
doi: 10.1182/blood-2011-05-351403
pubmed: 21931113
Lussana F, Intermesoli T, Gianni F, Boschini C, Masciulli A, Spinelli O, et al. Achieving Molecular Remission before Allogeneic Stem Cell transplantation in adult patients with Philadelphia chromosome–positive Acute Lymphoblastic Leukemia: impact on Relapse and Long-Term Outcome. Biol Blood Marrow Transpl. 2016;22:1983–7. https://doi.org/10.1016/j.bbmt.2016.07.021 .
doi: 10.1016/j.bbmt.2016.07.021
Nishiwaki S, Imai K, Mizuta S, Kanamori H, Ohashi K, Fukuda T, et al. Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph + ALL: a study from the adult ALL WG of the JSHCT. Bone Marrow Transpl. 2016;51:43–50. https://doi.org/10.1038/bmt.2015.217 .
doi: 10.1038/bmt.2015.217
Mizuta S, Matsuo K, Nishiwaki S, Imai K, Kanamori H, Ohashi K, et al. Pretransplant administration of imatinib for allo-HSCT in patients with BCR-ABL–positive acute lymphoblastic leukemia. Blood. 2014;123:2325–32. https://doi.org/10.1182/blood-2013-11-538728 .
doi: 10.1182/blood-2013-11-538728
pubmed: 24591204
Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:1522–31. https://doi.org/10.1182/blood-2017-08-798322 .
doi: 10.1182/blood-2017-08-798322
pubmed: 29358182
pmcid: 6027091
Litzow MR, Sun Z, Paietta E, Mattison RJ, Lazarus HM, Rowe JM, et al. Consolidation Therapy with Blinatumomab improves overall survival in newly diagnosed adult patients with B-Lineage Acute lymphoblastic leukemia in measurable residual disease negative remission: results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative clinical trials Network Trial. Blood. 2022;140:LBA–1. https://doi.org/10.1182/blood-2022-171751 .
doi: 10.1182/blood-2022-171751
Martinelli G, Boissel N, Chevallier P, Ottmann O, Gökbuget N, Topp MS, et al. Complete hematologic and molecular response in adult patients with relapsed/refractory philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol. 2017;35:1795–802. https://doi.org/10.1200/JCO.2016.69.3531 .
doi: 10.1200/JCO.2016.69.3531
pubmed: 28355115
Martinelli G, Boissel N, Chevallier P, Ottmann O, Gökbuget N, Rambaldi A, et al. Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome–positive B-cell precursor acute lymphoblastic leukaemia: final analysis of ALCANTARA study. Eur J Cancer. 2021;146:107–14. https://doi.org/10.1016/j.ejca.2020.12.022 .
doi: 10.1016/j.ejca.2020.12.022
pubmed: 33588145
Assi R, Kantarjian H, Short NJ, Daver N, Takahashi K, Garcia-Manero G, et al. Safety and Efficacy of Blinatumomab in Combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia. Clin Lymphoma Myeloma Leuk. 2017;17:897–901. https://doi.org/10.1016/j.clml.2017.08.101 .
doi: 10.1016/j.clml.2017.08.101
pubmed: 28927784
McCloskey JK, Gagnon J, McCabe T, Charlon J, Wang S, Fan R, et al. Blinatumomab in combination with tyrosine kinase inhibitors safely and effectively induces Rapid, Deep, and durable molecular responses in relapsed and refractory Philadelphia positive Acute Leukemias. Blood. 2019;134:3812. https://doi.org/10.1182/blood-2019-131838 .
doi: 10.1182/blood-2019-131838
Couturier M-A, Thomas X, Raffoux E, Huguet F, Berthon C, Simand C, et al. Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. Leuk Lymphoma. 2021;62:620–9. https://doi.org/10.1080/10428194.2020.1844198 .
doi: 10.1080/10428194.2020.1844198
pubmed: 33153370
Jabbour E, Haddad FG, Short NJ, Kantarjian H. Treatment of adults with Philadelphia chromosome–positive Acute Lymphoblastic Leukemia—from intensive chemotherapy combinations to chemotherapy-free regimens: a review. JAMA Oncol. 2022;8:1340–8. https://doi.org/10.1001/jamaoncol.2022.2398 .
doi: 10.1001/jamaoncol.2022.2398
pubmed: 35834222
Foà R, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo M-C, et al. Dasatinib–Blinatumomab for Ph-Positive Acute lymphoblastic leukemia in adults. N Engl J Med. 2020;383:1613–23. https://doi.org/10.1056/NEJMoa2016272 .
doi: 10.1056/NEJMoa2016272
pubmed: 33085860
Chiaretti S, Bassan R, Vitale A, Elia L, Piciocchi A, Viero P et al. P353: Forty Months Update of the GIMEMA LAL2116 (D-ALBA) Protocol and Ancillary LAL2217 Study for Newly Diagnosed Adult PH + ALL. HemaSphere. 2022;6:253. https://doi.org/10.1097/01.HS9.0000844300.04335.af .
Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, et al. Ponatinib and Blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2023;10(e24–34). https://doi.org/10.1016/S2352-3026(22)00319-2 . This study reports the results of a phase II study examining the efficacy of ponatinib and blinatumomab in newly diagnosed or refractory/refractory Ph + ALL. This chemotherapy-free combination resulted in high rates of complete remission and MRD negativity, even in the relapsed/refractory setting.
Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016;375:740–53. https://doi.org/10.1056/NEJMoa1509277 .
doi: 10.1056/NEJMoa1509277
pubmed: 27292104
pmcid: 5594743
Stock W, Martinelli G, Stelljes M, DeAngelo DJ, Gökbuget N, Advani AS, et al. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia. Cancer. 2021;127:905–13. https://doi.org/10.1002/cncr.33321 . This study reports the results of the INO-VATE open-label, randomized, phase 3 trial that examined the efficacy of inotuzumab ozogamicin in relapsed/refractory Ph + ALL. Compared with standard of care, inotuzumab demonstrated superior rates of complete remission/complete remission with incomplete hematologic recovery and MRD negativity.
doi: 10.1002/cncr.33321
pubmed: 33231879
Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gökbuget N, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019;125:2474–87. https://doi.org/10.1002/cncr.32116 .
doi: 10.1002/cncr.32116
pubmed: 30920645
DeAngelo DJ, Stock W, Stein AS, Shustov A, Liedtke M, Schiffer CA, et al. Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. Blood Adv. 2017;1:1167–80. https://doi.org/10.1182/bloodadvances.2016001925 .
doi: 10.1182/bloodadvances.2016001925
pubmed: 29296758
pmcid: 5728308
Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric Antigen Receptor T Cells for sustained remissions in Leukemia. N Engl J Med. 2014;371:1507–17. https://doi.org/10.1056/NEJMoa1407222 .
doi: 10.1056/NEJMoa1407222
pubmed: 25317870
pmcid: 4267531
Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in Children and Young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–48. https://doi.org/10.1056/NEJMoa1709866 .
doi: 10.1056/NEJMoa1709866
pubmed: 29385370
pmcid: 5996391
Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, et al. Three-year update of Tisagenlecleucel in Pediatric and Young Adult patients with Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial. J Clin Oncol. 2023;41:1664–9. https://doi.org/10.1200/JCO.22.00642 .
doi: 10.1200/JCO.22.00642
pubmed: 36399695
Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398:491–502. https://doi.org/10.1016/S0140-6736(21)01222-8 .
doi: 10.1016/S0140-6736(21)01222-8
pubmed: 34097852
Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study. J Hematol OncolJ Hematol Oncol. 2022;15:170. https://doi.org/10.1186/s13045-022-01379-0 .
doi: 10.1186/s13045-022-01379-0
Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. Updated outcomes from the historical control study SCHOLAR-3 contextualizing ZUMA-3 results of Brexucabtagene Autoleucel (KTE-X19) in adult patients with relapsed or refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL). Blood. 2022;140:3158–61. https://doi.org/10.1182/blood-2022-158248 .
doi: 10.1182/blood-2022-158248
*Nishiwaki S, Sugiura I, Fujisawa S, Hatta Y, Atsuta Y, Doki N et al. Utility of allogeneic stem cell transplantation for adult Ph + ALL with complete molecular remission. Am J Hematol. 2024;99:806–15. https://doi.org/10.1002/ajh.27237 . This retrospective study compared outcomes between 147 Ph + ALL patients in complete molecular response after induction who did or did not undergo allogeneic HCT. Results demonstrated that allogeneic HCT led to superior OS and RFS.
**Foà R, Bassan R, Elia L, Piciocchi A, Soddu S, Messina M et al. Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL. J Clin Oncol. 2024;42:881–5. https://doi.org/10.1200/JCO.23.01075 . This study provided long-term results of the GIMEMA LAL2116, D-ALBA trial that studied the combination of dasatinib and blinatumomab in the frontline setting for Ph + ALL. This results showed that almost all MRD-negative patients remained in long-term remission without HCT, and that the clear benefit of HCT was seen in MRD-positive patients.
Chalandon Y, Thomas X, Hayette S, Cayuela J-M, Abbal C, Huguet F, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015;125:3711–9. https://doi.org/10.1182/blood-2015-02-627935 .
doi: 10.1182/blood-2015-02-627935
pubmed: 25878120
Ghobadi A, Slade M, Kantarjian H, Alvarenga J, Aldoss I, Mohammed KA, et al. The role of allogeneic transplant for adult Ph + ALL in CR1 with complete molecular remission: a retrospective analysis. Blood. 2022;140:2101–12. https://doi.org/10.1182/blood.2022016194 .
doi: 10.1182/blood.2022016194
pubmed: 35877996
pmcid: 9837437
Sasaki K, Kantarjian HM, Short NJ, Samra B, Khoury JD, Kanagal Shamanna R, et al. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer. 2021;127:2648–56. https://doi.org/10.1002/cncr.33529 .
doi: 10.1002/cncr.33529
pubmed: 33793964
Foà, Robin. Chiaretti Sabina. Philadelphia chromosome–positive Acute Lymphoblastic Leukemia. N Engl J Med. 2022;386:2399–411. https://doi.org/10.1056/NEJMra2113347 .
doi: 10.1056/NEJMra2113347
pubmed: 35731654